Evogene (EVGN) Q2 2026 earnings review
Survival Through Shrinkage: Evogene Bets It All on AI Platform
Evogene is completing a brutal but necessary transformation. The company has shrunk its workforce by nearly 70% and sold off legacy agricultural businesses to survive. The result is a dramatically decelerating cash burn and a narrowed operating loss of $2.56M for Q2 2026. Top-line revenue remains stagnant at just $0.35M, reflecting the scale-down of legacy seed sales. However, the future is now entirely tethered to the ChemPass AI platform, which has expanded its virtual chemical space to 110 billion molecules and secured six drug development collaborations. The strategy is clear: survive long enough on divested asset cash to sign a transformative, revenue-generating deal in the pharma or ag-chemical space.
🐂 Bull Case
Management expects FY26 cash usage of $8.5M–$9.5M, down sharply from $14.4M in FY25 and $20.5M in FY24. Dividends received from divested units ($4.25M from Lavie Bio, $1.35M from Biomica) provide a crucial lifeline to execute the AI strategy.
The ChemPass AI platform now boasts six active pharma collaborations. Expanding the virtual compound library to 110 billion molecules and integrating Google Cloud's AI agents gives Evogene a competitive moat in computational chemistry.
🐻 Bear Case
With the scale-down of Casterra and the termination of the Bayer collaboration earlier this year, revenue is effectively flatlining at ~$350K per quarter. The company has no immediate, scalable commercial revenue streams.
Even with an optimized cost structure, the $9.3M cash balance (plus recent dividends) only buys about 12-18 months of runway. If significant upfront milestone payments from 'big pharma' do not materialize soon, dilution is inevitable.
⚖️ Verdict: ⚪
Neutral. Management has successfully executed the cost-cutting and streamlining phase of their turnaround. However, the company is now a high-risk, pre-revenue biotech platform play. The underlying technology is promising, but the financial margin for error is zero.
Key Themes
ChemPass AI Technological Leap
Evogene's core value proposition is accelerating. The company expanded its virtual chemical space by 300%, growing from 36 billion to 110 billion unique, accessible molecules. Additionally, they integrated autonomous AI Agents via Google Cloud, allowing the automation of research tasks that used to take months into a matter of minutes. This is a crucial technological driver for securing high-value pharmaceutical partnerships.
Relentless Cost Cutting and Restructuring
The company has right-sized its operations to fit its new identity. Headcount was slashed from 117 in December 2024 to just 38 in August 2026. This drove a structural drop in R&D and SG&A expenses, allowing management to guide for a decelerating cash burn of ~$9.0M at the midpoint for FY26. Divestments of Lavie Bio and Biomica successfully isolated cash drains while generating dividend injections.
Pharma Pipeline Traction
The pivot to pharma is showing early operational success. Evogene signed four new drug development collaborations in 2026, bringing the total to six. More importantly, two of these programs have already passed the initial 'Hit Identification' stage of the ChemPass AI process, exceeding partner expectations. These milestones validate the platform's utility in high-value human health markets.
Revenue Collapse Post-Restructuring
Reversing its previous growth profile, H1 2026 revenue fell to $0.68M from $2.88M in H1 2025. This $2.2M decline is directly tied to the cessation of significant Casterra seed sales. While management touts the AI platform, the reality is that legacy operations have been effectively shuttered before the new AI strategy can fill the revenue void.
Geopolitical and Regional Macro Risk
The company's primary operations and personnel are based in Rehovot, Israel. Forward-looking statements continue to explicitly warn of risks stemming from the ongoing conflicts with Hamas, Hezbollah, and Iran. While not directly quantified in the Q2 results, regional destabilization remains a persistent macro overhang that could disrupt critical R&D timelines or deter risk-averse multinational partners.
Financial Noise vs Core Performance
Management highlights a significantly improved Net Loss ($1.8M in Q2 2026 vs $4.7M in Q2 2025). However, this positive narrative contradicts the underlying operational reality. Much of the net loss improvement was driven by $1.14M in non-cash financing income related to the revaluation of warrant liabilities. When stripping away this accounting noise, the operating loss of $2.56M remains a truer, less flattering picture of the core business's cash-generating ability.
Other KPIs
Decelerating. Down from $1.67 million in Q2 2025. The decrease is primarily attributable to lower expenses in the Casterra subsidiary, reflecting the company's shift of capital away from agriculture execution and exclusively into its core AI platform.
Down from $12.96 million at the end of FY25. The company used $2.1 million in operating cash during Q2. This balance does not fully capture post-quarter liquidity injections, such as the scheduled receipt of $2.9M from Lavie Bio and $1.35M from Biomica, which are critical to maintaining the 18-month runway.
Guidance
Decelerating sharply. The midpoint of $9.0M implies a 37.5% reduction in annual cash burn compared to the $14.4M utilized in FY25. This guidance confirms that the extreme headcount reductions and subsidiary wind-downs have successfully reset the company's cost baseline.
Key Questions
Monetization Timeline for ChemPass AI
With six active pharma collaborations now underway and some passing Hit Identification, what is the expected timeline for these partnerships to transition from early-stage validation to generating meaningful, non-dilutive milestone payments?
Casterra Brazil Strategy
Casterra's operations are now exclusively focused on Brazil. Given the complete collapse in legacy seed sales, what are the specific commercial milestones and capital requirements for the Brazilian market over the next 12-18 months?
Capital Needs Beyond 2026
Assuming the FY26 cash burn guidance of $8.5-$9.5M is met, the current cash balance combined with subsidiary dividends provides a runway into late 2027. Is management currently exploring strategic equity investments from existing tech or pharma partners to secure the balance sheet long-term?